6. Mira (Quanovate)

Founders: Bin Miao, Sylvia Kang and Zheng Yang

Website: https://www.miracare.com/

Business: Develops home healthcare products such as Mira Fertility – an AI-powered device that aims to help women who are struggling to conceive.

Quanovate Tech Inc. (Mira) is a San-Francisco-based company that provides healthcare products for more personal, accurate, and reliable home healthcare. It was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing.

Prior to its public launch in 2018, Mira had raised $6 mn from investors, then quickly reached self-sufficiency and was able to grow at the expense of profit. The company grows exponentially, attracting on average 20% more users each year.

The Company’s first healthcare product for at-home testing — Mira Fertility — is an AI-powered device that aims to help women who are struggling to conceive. It measures numeric concentrations of hormones like in a lab directly from their bathrooms. 99% accuracy proven in trials.

Currently, the device tests for the concentrations of LH (luteinizing hormone), which is an indicator of ovulation, E3G (estrogen), which is a key component in understanding reproductive health, and PdG (the urine metabolite of progesterone), which confirms ovulation, and will soon track FSH (Follicle-Stimulating Hormone) and hCG (Human chorionic gonadotropin).

While being the only home testing product that can measure multiple hormones and track women’s health comprehensively with laboratory-grade accuracy, OB and IVF clinics also widely use Mira in order to obtain continuous hormone data to make diagnostic decisions, saving cost of frequency blood drawing and providing better experience to the clinic and patients.

In the future, Mira plans to expand the system’s AI-powered analysis and capabilities to test for chronic disease, infectious disease, vitamin levels, influenza, allergen sensitivity, kidney health, thyroid hormones, gout, and general wellness monitoring.

Starting from its launch in September, 2018, Mira helped over 30K women worldwide reach their fertility goals while empowering them with the crucial knowledge on their own bodies and their data. Over 60,000 Mira analysers have been shipped to date. During the challenging pandemic year, Mira has shown a 7-fold increase in annual revenue.

As the women’s health-tech market is expected to generate at least $3 billion by 2030, according to PitchBook, the future of Mira is much more than just a fertility tracker – with all major female hormones on the panel, Mira will be the only home test device able to track women’s overall reproductive health.

Does Your Business Need Funding? Get Funding – Enquire Today >>>